Application of Bioluminescence Imaging to the Prediction of Lethality in Vaccinia Virus-Infected Mice
- 15 October 2009
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 83 (20) , 10437-10447
- https://doi.org/10.1128/jvi.01296-09
Abstract
To find an alternative endpoint for the efficacy of antismallpox treatments, bioluminescence was measured in live BALB/c mice following lethal challenge with a recombinant WR vaccinia virus expressing luciferase. Intravenous vaccinia immunoglobulin treatments were used to confer protection on a proportion of animals. Using known lethality outcomes in 200 animals and total fluxes recorded daily in live animals, we performed univariate receiver operating characteristic (ROC) curve analysis to assess whether lethality can be predicted based on bioluminescence. Total fluxes in the spleens on day 3 and in the livers on day 5 generated accurate predictive models; the area under the ROC curve (AUC) was 0.91. Multiple logistic regression analysis utilizing a linear combination of six measurements: total flux in the liver on days 2, 3, and 5; in the spleen on days 1 and 3; and in the nasal cavity on day 4 generated the most accurate predictions (AUC = 0.96). This model predicted lethality in 90% of animals with only 10% of nonsurviving animals incorrectly predicted to survive. Compared with bioluminescence, ROC analysis with 25% and 30% weight loss as thresholds accurately predicted survival on day 5, but lethality predictions were low until day 9. Collectively, our data support the use of bioimaging for lethality prediction following vaccinia virus challenge and for gaining insight into protective mechanisms conferred by vaccines and therapeutics.Keywords
This publication has 25 references indexed in Scilit:
- Applications of bioluminescence imaging to antiviral research and therapy: Multiple luciferase enzymes and quantitationAntiviral Research, 2008
- Discovery of antivirals against smallpoxProceedings of the National Academy of Sciences, 2004
- Antiviral prophylaxis of smallpoxJournal of Antimicrobial Chemotherapy, 2004
- Smallpox DNA Vaccine Protects Nonhuman Primates against Lethal MonkeypoxJournal of Virology, 2004
- Intravenous immunoglobulin products contain neutralizing antibodies to vacciniaVox Sanguinis, 2004
- Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison with the Western Reserve Strain and Advantages as a VaccineJournal of Virology, 2000
- Mucosal and systemic immune responses induced after oral delivery of vaccinia virus recombinantsVaccine, 1999
- Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory routeJournal of General Virology, 1990
- Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals.Proceedings of the National Academy of Sciences, 1988
- Target cell‐dependent T cell‐mediated lysis of vaccinia virus‐infected cellsEuropean Journal of Immunology, 1975